Kowa Research Institute, Inc. clinical trials

A subsidiary of Kowa Company, Ltd.

The registry lists 47 studies whose lead sponsor is Kowa Research Institute, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 47 of 47. All Kowa Company, Ltd. studies →

• Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract ExtractionNot yet recruitingNCT07650201Not applicable

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.CompletedNCT06247735Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCompletedNCT05528172Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisCompletedNCT05327127Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedNCT05795699Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedNCT05826353Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)TerminatedNCT03071692Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.CompletedNCT06525311Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye DiseaseCompletedNCT05403827Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study to Evaluate the Efficacy and Safety of K-285 Compared With Menthol Gel for the Treatment of Delayed Onset Muscle Soreness (DOMS) in the Lower ExtremityTerminatedNCT04484428Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following DescemetorhexisCompletedNCT04250207Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IRCompletedNCT04447820Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452CompletedNCT05722262Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye DiseaseCompletedNCT04084483Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal FunctionCompletedNCT03001817Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal ImpairmentCompletedNCT03011450Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Assess the Food Effect of K-877 in Healthy Adult VolunteersCompletedNCT04742218Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction of Lopinavir/Ritonavir on PitavastatinCompletedNCT01057433Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed DyslipidemiaWithdrawnNCT02799758Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed DyslipidemiaWithdrawnNCT02670434Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult VolunteersCompletedNCT04237597Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy AdultsCompletedNCT03712241Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.CompletedNCT03702673Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100CompletedNCT03505567Not applicable

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.TerminatedNCT02089425Phase 3

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult VolunteersCompletedNCT02922465Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult VolunteersCompletedNCT02719431Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312CompletedNCT02676830Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy SubjectsCompletedNCT02676596Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedNCT02275962Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult VolunteersCompletedNCT02634034Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Thorough Corrected QT Interval TrialCompletedNCT02073084Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedNCT02276001Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedNCT02275975Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedNCT02275988Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study in Health Adult VolunteersCompletedNCT02273986Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected SubjectsCompletedNCT01301066Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult VolunteersCompletedNCT01952548Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult VolunteersCompletedNCT01178853Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult VolunteersCompletedNCT01043094Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on PitavastatinCompletedNCT01422382Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Drug-Drug Interaction of Darunavir/Ritonavir on PitavastatinCompletedNCT01422369Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed DyslipidemiaCompletedNCT01256476Phase 4

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• Safety and Efficacy of K-134 for the Treatment of Intermittent ClaudicationCompletedNCT00783081Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin TherapyCompletedNCT01169090Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Trial of the Safety and Efficacy of K-604 for the Treatment of AtherosclerosisCompletedNCT00851500Phase 2

  Sponsor listed in the registry: Kowa Research Institute, Inc.

• A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403CompletedNCT01131091Phase 1

  Sponsor listed in the registry: Kowa Research Institute, Inc.